MDAI

Spectral AI is not an operating business in the normal sense — by management's own words in the MD&A, 'we have not generated any product revenue to date.' The $19.6M of FY2025 revenue is essentially government development funding, dominated by the BARDA Project BioShield contract, and it fell 33.6% YoY precisely because that contract is winding down: management says the current PBS award funding is 'expected to continue through the first quarter of 2026.' That is a revenue cliff, not a growth base, and the reported P/S of 2.9x is therefore meaningless as a valuation anchor. Revenue has been volatile and grant-driven for years ($25.4M → $18.1M → $29.6M → $19.6M), which is the signature of milestone billings, not commercial demand.

The balance sheet is stressed. Stockholders' equity is negative at -$5.73M with total liabilities ($27.1M) exceeding total assets ($21.4M), and accumulated deficit sits at -$55.8M. The company burned $9.92M of operating cash in FY2025 against $15.4M of cash on hand — barely over a year of runway once BARDA support rolls off. Shares outstanding already rose 25.7% YoY, so bridging that gap almost certainly means further dilution of a $57M market cap. The narrowing net loss (-$7.57M vs -$15.2M) is a positive, but it coincides with shrinking revenue, so it reflects lower activity rather than emerging operating leverage.